Evidence map›Paper›PMID 26863991›Full record

ArticleDiabetes, obesity & metabolism2016

L-arginine promotes gut hormone release and reduces food intake in rodents.

A Alamshah, A K McGavigan, E Spreckley, J S Kinsey-Jones, A Amin, I R Tough, H C O'Hara, A Moolla, K Banks, R France and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Diabetes, obesity & metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review.Advances in nutrition (Bethesda, Md.) · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

A AlamshahSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
A K McGaviganSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
E SpreckleySection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
J S Kinsey-JonesSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
A AminSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
I R ToughWolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
H C O'HaraSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
A MoollaSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
K BanksSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
R FranceSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
G HybergAstraZeneca R&D, Mölndal, Sweden.
M NortonSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
W CheongSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
A LehmannAstraZeneca R&D, Mölndal, Sweden.
S R BloomSection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
H M CoxWolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
K G MurphySection of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK.
Imperial College London · GBAstraZeneca (Sweden) · SEKing's College London · GB

Funding

Biotechnology and Biological Sciences Research Council BB/E52708X/1Biotechnology and Biological Sciences Research Council BB/I001816/1Medical Research Council G0000566Medical Research Council G0802390Medical Research Council G7811974Medical Research Council MR/J010944/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/K500379/1
6 · The paper itself

Abstract

aimsTo investigate the anorectic effect of L-arginine (L-Arg) in rodents.

methodsWe investigated the effects of L-Arg on food intake, and the role of the anorectic gut hormones glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), the G-protein-coupled receptor family C group 6 member A (GPRC6A) and the vagus nerve in mediating these effects in rodents.

resultsOral gavage of L-Arg reduced food intake in rodents, and chronically reduced cumulative food intake in diet-induced obese mice. Lack of the GPRC6A in mice and subdiaphragmatic vagal deafferentation in rats did not influence these anorectic effects. L-Arg stimulated GLP-1 and PYY release in vitro and in vivo. Pharmacological blockade of GLP-1 and PYY receptors did not influence the anorectic effect of L-Arg. L-Arg-mediated PYY release modulated net ion transport across the gut mucosa. Intracerebroventricular (i.c.v.) and intraperitoneal (i.p.) administration of L-Arg suppressed food intake in rats.

conclusionsL-Arg reduced food intake and stimulated gut hormone release in rodents. The anorectic effect of L-Arg is unlikely to be mediated by GLP-1 and PYY, does not require GPRC6A signalling and is not mediated via the vagus. I.c.v. and i.p. administration of L-Arg suppressed food intake in rats, suggesting that L-Arg may act on the brain to influence food intake. Further work is required to determine the mechanisms by which L-Arg suppresses food intake and its utility in the treatment of obesity.

Indexed as

Dietary SupplementsAnimalsAppetite DepressantsArginineCells, CulturedEnergy IntakeEnergy MetabolismGastrointestinal AgentsGlucagon-Like Peptide 1Injections, IntraperitonealInjections, IntraventricularIntestinal MucosaIn Vitro TechniquesMaleMice, Inbred C57BLMice, KnockoutAppetite DepressantsArginineGastrointestinal AgentsGlucagon-Like Peptide 1GPRC6A protein, mousePeptide YYReceptors, G-Protein-Coupledanimal pharmacologybody compositionenergy regulationGLP-1obesity therapy

Identifiers

PMID26863991
PMCPMC4982043
OpenAlexW2260142409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.